BioPharma Dive May 22, 2024
Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.
Eli Lilly and Pfizer have both recently launched direct-to-consumer platforms allowing patients to bypass an in-person doctor visit or brick-and-mortar pharmacy. Their decisions suggest large pharmaceutical companies are exploring new ways to reach patients and could indicate a growing trend.
Lilly introduced LillyDirect, its direct-to-consumer platform, at the beginning of the year with the aim of “simplifying the patient experience,” said CEO David Ricks. The online platform offers disease management for diabetes, migraine and obesity, with a telehealth program to connect users with healthcare professionals who can prescribe medications delivered to the home.
In March, Lilly...
Today's Sponsors
Today's Sponsor